Hematologic changes after splenectomy for cytoreduction: implications for predicting infection and effects on chemotherapy. Issue 6 (1st October 2006)

• Record Type: Journal Article
• Authors: Bidus, M. A.; Krivak, T. C.; Howard, R.; Rose, G. S.; Cosin, J.; Dainty, L.; Elkas, J. C.
• Is Part Of: International journal of gynecological cancer. Volume 16:Issue 6(2006)
• Page Start: 1957
• Page End: 1962
• Publication Date: 2006-10-01
• Subjects: splenectomy -- cytoreduction -- chemotherapy -- infection -- ovarian cancer; Generative organs, Female -- Cancer -- Periodicals; 616.99465
• DOI: 10.1111/j.1525-1438.2006.00725.x
• Languages: English
• ISSNs: 1048-891X

Abstract

Abstract : Postsplenectomy leukocytosis and thrombocytosis are common findings in trauma patients. The intent of this study is to describe postsplenectomy hematologic changes in gynecological oncology surgery and subsequent chemotherapy. We performed a retrospective record review of gynecological oncology patients at our institutions. Postsurgical hematologic changes, infectious morbidity, and pre- and post-chemotherapy hematologic changes were noted. Data were analyzed using repeated measures analysis of variance. We identified 27 patients who underwent cytoreductive surgery with splenectomy. Thirteen patients with splenectomy had postoperative chemotherapy data available, and we matched these patients with 13 control patients who underwent cytoreduction surgery without splenectomy and postoperative chemotherapy. Nine of the 27 splenectomy patients had documented infectious morbidity. There was a significant difference in postoperative platelet counts between the infected and the noninfected splenectomy patients ( P = 0.037), and a significant difference between splenectomy and control patients for white blood cell (WBC) counts ( P = 0.007). Patients with splenectomy had higher precycle WBC, absolute neutrophil count (ANC), platelet counts, and higher postcycle nadir levels in all cycles compared to control patients. There was a significant overall difference between splenectomy patients and controls with regard to WBC ( P = 0.001), ANC ( P = 0.005), and platelet counts ( P = 0.016) during chemotherapy cycles. Median postchemotherapy nadir WBC was 4.4 (range: 3.4–4.8) for the splenectomy group versus 2.8 (range: 2.5–3.0) for the control group. Median postchemotherapy nadir ANC was 1800 (range: 1320–2450) for the splenectomy group and 1001 (range: 864–1064) for the control group. Median postchemotherapy nadir platelet count was 222 (range: 181–277) for the splenectomy patients and 169 (range 164–215) for the control patients. In conclusion, the patients who undergo splenectomy as part of cytoreductive surgeries have a statistically significant leukocytosis and insignificant thrombocytosis relative to the control patients. Leukocytosis alone is not an accurate indicator of infection. Splenectomy is not associated with an increased risk of chemotherapy-related neutropenia and thrombocytopenia.